Health

A New Drug Could Treat Type 2 Diabetes

AI Medicine Pharmaceutical Drugs

The drug has already been successfully tested in animal studies.

Scientists develop a new drug candidate to treat diabetes.

A novel hormone combination has been created by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the potential treatment of type 2 diabetes in the future. The researchers combined the blood sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to create a new and extremely effective drug.

The benefit of combining Tesaglitazar with GLP-1 is that the Tesaglitazar only penetrates the tissue with GLP-1 receptors. This increases the effects on sugar metabolism while lessening the side effects of tesaglitazar. Scientists have already successfully tested the new drug in animal studies. The study was recently published in the journal Nature Metabolism

Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic patients. It increases insulin sensitivity by acting on two receptors inside the cell nucleus. This was demonstrated in phase 3 clinical trials. However, tesaglitazar has side effects such as kidney damage.

The new drug candidate (GLP-1/tesaglitazar) enhanced improvements of body weight, food intake, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in obese male mice. Credit: Helmholtz Munich

However, in order to utilize the drug therapeutically, the researchers employed a trick: they biochemically combined tesaglitazar with the gastrointestinal hormone GLP-1. As a result, the combined drug can only work on cells and tissues that have GLP-1 receptors.

“This trick enabled us to combine the blood sugar-reducing effects of GLP-1 and tesaglitazar into a single highly effective molecule while keeping tesaglitazar away from tissues that it could damage,” explains PD Dr. Timo Müller, corresponding author, director of the Institute of Diabetes and Obesity, and scientist at DZD.

The new drug improves glucose tolerance and sugar metabolism

The new drug has already been successfully tested in animal studies: “The sugar metabolism of obese and diabetic male mice improved to a far greater extent compared with treatment using only the GLP-1 hormone or tesaglitazar alone – and with no damaging adverse effects to the liver or kidney,” says Professor Kerstin Stemmer, one of the lead authors of the study.

The substance was particularly effective in increasing glucose tolerance levels. Only minimal doses of the new drug were required to achieve sustainable improvement of glucose metabolism.

“This drug has great potential for the acute treatment of elevated blood sugar levels associated with type 2 diabetes,” says Aaron Novikoff, another lead author of the study.

The researchers now want to investigate whether this drug also has the potential to treat humans with type 2 diabetes and whether the efficacy of this new combination therapy can be optimized further using biochemical modifications.

Background:

The team comprised of Professor Dr. Matthias Tschöp (scientific director of Helmholtz Munich), PD Dr. Timo Müller, Richard DiMarchi, Ph.D. (Indiana University), and Dr. Brian Finan (Novo Nordisk) has been working for many years on new drug candidates for the treatment of type 2 diabetes and obesity. Poly-agonists simultaneously mimic the effects of various hormones. Clinical trials have shown that some poly-agonists are exceptionally promising in the treatment of obesity and type 2 diabetes and are already in phase 2 and phase 3 trials.

This year in the USA the first dual agonist drug for the treatment of type 2 diabetes was approved. The drug combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists that mimic the effects of the intestinal hormones GLP-1 and GIP.

Reference: “GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice” by Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, and Timo D. Müller, 22 August 2022, Nature Metabolism.
DOI: 10.1038/s42255-022-00617-6

Share

View Comments

  • I'm so excited about this. Hope it gets to patients sooner rather than later. Thankyou to all the people involved in working on this. You will be changing people's lives!!!!!!

  • So they combined two known drugs into one. A lot like taking the two drugs separately. Wake me when the excitement dies down.

  • I really appreciate it can be helpful to my type 2 diabetes and weight loss hoping for the best part of a now drug thank you for This information

  • Husband is skinny diabetic and dependent on insulin, any updates on drug info, trials, or ways to help him gain weight without carbs or affecting his heart health would be appreciated

  • Wouldn't a better solution be to eat without spiking blood glucose (and insulin). After all a key problem with diabetics (and many with metabolic syndrome) is hyperinsulinemia. Dealing solely with blood glucose seems to be missing the mark altogether.

By
German Center for Diabetes Research, DZD

Recent Posts

NASA Scientists Use Discover Supercomputer To Create Black Hole Jets

NASA Goddard Space Flight Center scientists ran 100 sophisticated simulations exploring jets — narrow beams…

November 30, 2022

SOFIA Finds No Phosphine – a Potential Sign of Life – on Venus

Venus is considered Earth’s twin in many ways. However, recent observations made with the Stratospheric…

November 30, 2022

Too Much Motivation Affects Your Perception and Decision-Making

An EPFL and UNIGE team demonstrates how motivation affects the neural circuits of perception and…

November 30, 2022

New Form of Antimicrobial Resistance Discovered – One of the World’s Greatest Health Threats

Australian scientists have uncovered a new form of antimicrobial resistance – undetectable using traditional laboratory…

November 30, 2022

Two Minerals – Never Before Seen on Earth – Discovered in Massive Meteorite

New minerals discovered in massive meteorite may reveal clues to asteroid formation. At least two…

November 30, 2022

NASA Artemis I – Flight Day 14: Deep Space Testing Continues

Artemis I launched on November 16, with the powerful Space Launch System rocket carrying Orion…

November 30, 2022